Phase II study with 3rd- or 4th-line bendamustine (flat dose) therapy in patients with metastatic breast cancer

Onkologie

Volumn 32, Issue 8-9, 2009, Pages 488-492

  Steinbild, Simone ^a   Frost, Annette ^a   Häring, Brigitte ^a   Unger, Clemens ^a   Mross, Klaus ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Bendamustine; Fixed flat dose; Metastatic breast cancer; Phase II study

Indexed keywords

ANTHRACYCLINE; BENDAMUSTINE; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL COUNT; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIARRHEA; DRUG DOSE; DRUG EFFICACY; EDEMA; FATIGUE; FEVER; FIXED FLAT DOSE; HUMAN; INFECTION; LABORATORY TEST; LEUKOPENIA; LIVER METABOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; METHODOLOGY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RESISTANCE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERMANY; HUMANS; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; TREATMENT OUTCOME;

EID: 70149107712     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226137     Document Type: Article

References (17)

1. Schrijvers D, Vermorken JB: Phase I studies with bendamustine: an update. Semin Oncol 2002;29:15-18.
2. Lissitehkov T, Arnaudov G, Peytehev D, Merkle KH: Phase-I/II study to evaluate dose limiting toxieity, maximum tolerated dose, and tolerability of bendamustine HC1 in pretreated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006;132:99-104.
3. Borchmann P, Schnell R, Diehl V, Engert A: New drugs in the treatment of Hodgkin's disease. Ann Oncol 1998;9(suppl 5):S103-S108.
4. Bemer K: High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002;128:603-609.
5. Schmittel A, Knodler M, Hortig P, Schulze K, Thiel E, Keilholz U: Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007;55:109-113.
6. Jamitzky T, Lange OF: Third-line chemotherapy with bendamustine for metastatic breast cancer. A prospective pilot study. 7th EORTC Breast Cancer Working Conference. Abstract PP-7-14. Eur J Cancer 1996;32A(suppl 2):47.
7. Hoffken K, Merkle K, Schonfelder M, Anger G, Brandtner M, Ridwelski K, Seeber S: Bendamustine as salvage treatment in patients with advanved progressive breast cancer. A phase II study. J Cancer Res Clin Oncol 1998;124:627-632.
8. Reichmann U, Bokemeyer C, Wallwiener D, Bam-berg M, Huober J: Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. Ann Oncol 2007;18:1981-1984.
9. Baker SD, Verweij J, Rowinsky E, et al.: Role of body surface area in dosing of investigational an-ticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94:1883-1888.
10. DeJongh FE, Verweij J, Loos WJ, et al.: Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001;19:3733-3739.
11. Mathijssen RHJ, Verweij J, de Jonge MJA, et al.: Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002;20:81-87.
12. Dobbs NA, Twelves CJ: What is the effect of adjusting epirubicin doses for body surface area? Br J Cancer 1998;78:662-666.
13. Ratain MJ: Body surface area as a basis for dosing of anticancer agents: science, myth or habit? J Clin Oncol 1998;16:2297-2298.
14. Therasse P, Arbuck SG, Eisenhauer AE, et al.: New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst 2000;92:205-216.
15. Ruffert K: Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochlo-mide, methotrexate and fluorouracil. Zen -phosphamide, methotrexate and fluorouracil. Zen-tralbl Chir 1998;123(suppl 5):156-158.
16. Von Minckwitz G, Chernozemsky I, Sirakova L, et al.: Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005;16:871-877.
17. Brockmann B, Geschke E, Schmidt UM, et al.: Therapeutic results and toxic side effects oft the combination of cytostasan, adriamycin and vincris-tin as second-line therapy of metastatic breast cancer. Geburtshilfe Frauenheilkd 1991;51:383-386.